生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

已收盘 06-16 16:00:00 EDT

1,127.72

-0.75

-0.07%

最高1,133.55	最低1,117.95	成交量19.26亿
今开1,128.47	昨收1,128.47	日振幅1.38%
总市值0.00	流通市值0.00	总股本0.00
成交额173.60亿	换手率--	流通股本0.00
市净率6.84471	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1127.7189,"timestamp":1781639999999,"preClose":1128.4713,"halted":0,"volume":1925986305,"delay":0,"changeRate":-0.000667,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-0.752441,"latestTime":"06-16 16:00:00 EDT","open":1128.4727,"high":1133.5493,"low":1117.9546,"amount":17360468585.358276,"amplitude":0.013819,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781683200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.84471,"peRate":-150.215065,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139/wiki","defaultTab":"wiki","newsList":[{"id":"1181457174","title":"Precision BioSciences与加州银行签署贷款及担保协议第一修正案","url":"https://stock-news.laohu8.com/highlight/detail?id=1181457174","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181457174?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:04","pubTimestamp":1781640252,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件显示，Precision BioSciences公司已与加州银行就其贷款及担保协议签署了第一修正案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DTIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130135230","title":"Verastem Oncology启动VS-7375治疗Kras G12d突变胰腺癌II期注册试验，首位患者已用药","url":"https://stock-news.laohu8.com/highlight/detail?id=1130135230","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130135230?lang=zh_cn&edition=full","pubTime":"2026-06-17 04:02","pubTimestamp":1781640137,"startTime":"0","endTime":"0","summary":"Verastem Oncology宣布，其针对Kras G12d突变转移性胰腺癌的口服抑制剂VS-7375，已在名为Target-D 201的II期注册导向试验中，为第一位患者完成给药。这项关键性研究旨在评估该药物的疗效与安全性，标志着该创新疗法向潜在注册上市迈出了实质性一步。VS-7375是一种新型的Kras G12d（开/关）抑制剂，其设计旨在精准靶向这一在胰腺癌中常见的特定基因突变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VSTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188525350","title":"Canton Strategic 批准高达5000万美元的普通股回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1188525350","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188525350?lang=zh_cn&edition=full","pubTime":"2026-06-16 21:07","pubTimestamp":1781615263,"startTime":"0","endTime":"0","summary":"Canton Strategic Holdings Inc 于6月16日宣布，已授权一项新的股票回购计划。根据公司向美国证券交易委员会提交的文件，该计划授权公司回购价值不超过5000万美元的普通股。\n这一举措表明，公司管理层认为其股票当前市场价值被低估，并致力于通过资本配置为股东创造价值。股票回购计划通常有助于提升每股收益，并为市场提供积极的信号。\n该计划的授权，为Canton Strategic 在未来根据市场情况灵活执行回购操作提供了空间。具体回购的时机、数量和价格将取决于市场状况、监管要求以及公司的现金状况。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0158827948.USD","LU1121112475.USD","LU2091194634.USD","IE0004091025.USD","LU1153584641.USD","IE00BKPKM429.USD","LU2095319765.USD","LU1078025761.USD","IE00BQXX3D17.EUR","LU0511384066.AUD","BK4585","LU0175139822.USD","LU2111349929.HKD","LU2506951958.HKD","BK4588","LU0057025933.USD","LSEG.UK","LU0426412945.USD","LU0963555726.SGD","LU0158827781.USD","LU0171280430.USD","LU2506951875.HKD","LU1019634622.SGD","CNTN","LU0994945656.USD","LU1228905540.USD","LU0887340254.USD","LU1355424745.HKD","LU2210150020.SGD","LU0526926950.USD","IE00BQXX3F31.USD","LU1003076772.USD","LU0345777659.USD","IE00BQXX3C00.GBP","BK4596","LU1019632923.USD","LU0171293334.USD","LU1043141396.HKD","BK4504","LU2089283258.USD","LU2089284900.SGD","LU2506952097.USD","BK4559","LU1043141123.HKD","BK5051","LU2028103732.USD","LU2210149790.SGD","LU2506952170.USD","LU0289739343.SGD","LU1228905037.USD","LU0788108743.HKD","IE00BKPKM643.USD","LU1051770623.HKD","LU0314104364.USD","IE0004086264.USD","LU0472753341.HKD","LU0950375773.USD","BK4088","LU2114397693.USD","LU2023251221.USD","LU0069063385.USD","LEN","LU0823417737.USD","LU0969580561.USD","LU2271345857.HKD","LU0426417589.USD","LU0545562505.USD","LU0823417653.USD","BK4139","LU0289960550.SGD","LU0289961442.SGD","LU0345777147.USD","LU0171276677.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179067083","title":"FDA工作人员初步评估：Moderna流感疫苗数据或支持65岁及以上成人有效性","url":"https://stock-news.laohu8.com/highlight/detail?id=1179067083","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179067083?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:49","pubTimestamp":1781614183,"startTime":"0","endTime":"0","summary":"根据一份文件披露，美国食品药品监督管理局（FDA）工作人员已完成初步评估。其结论指出，Moderna公司提交的流感疫苗数据，可能为证明该疫苗对65岁及以上成年人群的有效性提供支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4532","BK4588","BK4139","BK4548","BK4551","BK4501","BK4568","MRNY","MRNA","BK4534","MRNX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124334353","title":"Moderna组织架构调整 为2027及2028年多款产品上市铺路","url":"https://stock-news.laohu8.com/highlight/detail?id=1124334353","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124334353?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:48","pubTimestamp":1781614130,"startTime":"0","endTime":"0","summary":"Moderna, Inc. 正着手进行一系列组织架构调整，旨在为2027年和2028年可能推出的多款新产品做好充分准备。公司预计，在这两年内，有望上市多达三款新疫苗，其中包括一款流感与新冠二合一疫苗、季节性流感疫苗以及诺如病毒疫苗。为了支持这一雄心勃勃的商业化蓝图，Moderna已任命埃斯特·班克为公司首席商务官，该任命自2026年6月15日起生效。这些战略举措清晰地勾勒出Moderna为即将到来的产品上市浪潮所做的系统性准备。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4588","BK4551","MRNY","BK4534","MRNA","BK4533","BK4548","BK4532","BK4585","MRNX","BK4501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147188903","title":"Canton Strategic Holdings 授权最高5000万美元普通股回购计划 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1147188903","media":"美股速递","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147188903?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:34","pubTimestamp":1781613244,"startTime":"0","endTime":"0","summary":"Canton Strategic Holdings 已根据一份提交给美国证券交易委员会的文件，授权了一项新的股票回购计划。该公司获准在公开市场上回购其普通股，总金额最高可达5000万美元。此项授权标志着公司管理层对自身未来前景的信心，并可能旨在通过减少流通股数量来提升股东价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNTN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115715028","title":"FibroBiologics推进针对糖尿病足溃疡的Ciwc628药物1/2期临床试验患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1115715028","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115715028?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:31","pubTimestamp":1781613092,"startTime":"0","endTime":"0","summary":"FibroBiologics公司宣布，其用于治疗糖尿病足溃疡的研究性药物Ciwc628的1/2期临床试验已取得进展，进入患者给药阶段。这一步骤标志着该疗法在临床开发路径上的重要推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FBLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150085578","title":"Alpha Cognition宣布首位患者入组评估Zunveyl®用于轻中度阿尔茨海默病的Resolve第四期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1150085578","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150085578?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:30","pubTimestamp":1781613054,"startTime":"0","endTime":"0","summary":"Alpha Cognition Inc.宣布，其Resolve第四期研究已迎来首位患者入组。这项研究旨在评估Zunveyl®在轻至中度阿尔茨海默病患者中的疗效与安全性。该里程碑标志着公司在该药物临床开发进程中的关键一步，为后续数据收集与分析奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACOG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140127624","title":"Greenland Mines战略投资Anortech，布局可持续氧化铝、高纯氧化铝及中游关键矿物领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1140127624","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140127624?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:30","pubTimestamp":1781613036,"startTime":"0","endTime":"0","summary":"Greenland Mines宣布对Anortech进行战略投资，此举旨在拓展其在可持续氧化铝、高纯氧化铝以及中游关键矿物领域的业务版图与战略选择。通过这项投资，公司不仅强化了在关键矿物供应链中的地位，也为未来在绿色材料和高科技应用市场的发展增添了重要砝码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRML"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184245622","title":"CEL-SCI公司通过美国双重注册研究与沙特市场准入策略推进头颈癌免疫疗法Multikine®","url":"https://stock-news.laohu8.com/highlight/detail?id=1184245622","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184245622?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:05","pubTimestamp":1781611551,"startTime":"0","endTime":"0","summary":"CEL-SCI公司正通过一项双轨战略，推进其头颈癌免疫疗法Multikine®的研发与商业化进程。该战略一方面聚焦于在美国开展一项关键性的注册研究，旨在为产品上市铺平道路；另一方面，公司积极布局沙特阿拉伯市场，寻求新的商业机会。这一举措标志着该公司在拓展其核心肿瘤免疫治疗产品全球影响力的道路上迈出了重要步伐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CVM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141312126","title":"Acurx制药公司公布其DNA聚合酶IIIC抑制剂在莱顿大学医学中心公私合作项目中的研究结果，并于莱顿早期药物发现与开发科学会议上展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1141312126","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141312126?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:03","pubTimestamp":1781611404,"startTime":"0","endTime":"0","summary":"Acurx制药公司宣布，其针对DNA聚合酶IIIC抑制剂的研究成果，在莱顿大学医学中心主导的公私合作项目中取得进展。这些关键数据已在莱顿早期药物发现与开发科学会议上进行展示。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ACXP","BK4139","BK4563"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147262963","title":"艾伯维旗下爱力根美学获FDA批准，Juvéderm® Skinvive用于改善颈部外观","url":"https://stock-news.laohu8.com/highlight/detail?id=1147262963","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147262963?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:03","pubTimestamp":1781611401,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局已批准艾伯维公司旗下爱力根美学部门的Juvéderm Skinvive产品，用于改善成人颈部外观。该批准标志着这一透明质酸填充剂在美学应用领域获得了新的适应症。此次获批基于一项关键的临床研究数据，该研究证实了Skinvive在改善颈部皮肤质地和外观方面的有效性与安全性。作为艾伯维在医美领域的重要布局，Juvéderm系列产品此次拓展适应症，进一步巩固了其在全球填充剂市场的领先地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0000B7K699.USD","SG9999011175.SGD","LU0057025933.USD","LU1057294990.SGD","SG9999015952.SGD","IE00BVYPNV92.GBP","LU0661504455.SGD","LU2089984988.USD","LU2129689431.USD","LU1989772840.SGD","LU0943347566.SGD","BK4550","BK4566","LU1585245621.USD","LU1037948541.HKD","LU1551013342.USD","LU2347655156.SGD","LU0289961442.SGD","LU0553294199.USD","IE00BBT3K403.USD","LU1244550577.SGD","LU2357627491.SGD","IE00B19Z3581.USD","IE000BZT7R73.USD","LU2089283258.USD","LU2129689605.HKD","LU0795875086.SGD","LU1551013425.SGD","LU2237443895.HKD","LU1291159041.SGD","SG9999015986.USD","LU0122379950.USD","IE0009355771.USD","LU0738911758.USD","SG9999001440.SGD","LU0912757837.SGD","LU0823416689.USD","LU2237443622.USD","LU2112291526.USD","BK4585","LU0868494617.USD","LU1670628061.USD","LU0124676726.USD","LU0942090050.USD","LU0795875169.SGD","LU0689472784.USD","BK4139","IE0002270589.USD","IE00B19Z3B42.SGD","LU0203347892.USD","BK4559","LU1839511570.USD","IE00BLSP4239.USD","LU0114720955.EUR","LU0158827948.USD","LU1093756168.USD","LU0069063385.USD","IE00BGHQF631.EUR","LU0234572021.USD","LU1267930573.SGD","IE00BVYPNW00.USD","LU1496350502.SGD","LU0234570918.USD","LU0868494708.USD","LU0289739699.SGD","LU0211328371.USD","LU0417517546.SGD","SG9999003800.SGD","LU2237443382.USD","IE00BN8TJ469.HKD","LU0128525929.USD","LU0965509101.SGD","IE000WAW04H5.SGD","LU1061106388.HKD","LU1162221912.USD","LU2023251221.USD","LU0456855351.SGD","LU0198837287.USD","IE0004445239.USD","LU0310799852.SGD","LU2087621335.USD","LU0211327993.USD","LU1732799900.SGD","IE00B42XCP33.USD","LU0985320562.USD","LU1244550494.USD","LU0949170772.SGD","LU1037948897.HKD","LU0058720904.USD","LU0689626769.HKD","LU1074936037.SGD","LU1670627923.USD","IE00BJJMRZ35.SGD","LU0882574055.USD","SG9999015978.USD","LU1989771016.USD","IE00BSNM7G36.USD","LU1934455194.USD","LU0820561818.USD","IE00BDGV0183.EUR","LU1093756325.SGD","LU0170899867.USD","LU0203345920.USD","LU0965508806.USD","LU0511384066.AUD","ABBV","LU0289739343.SGD","LU0965509010.AUD","LU2237443978.SGD","IE0002141913.USD","LU0859254822.USD","LU0545039389.USD","LU1732800096.USD","IE00BLSP4452.SGD","IE000MB6IJN5.SGD","LU2237443465.HKD","IE00B4R5TH58.HKD","BK4581","LU0432979614.USD","LU0708994859.HKD","IE000SO60NU8.SGD","BK4533","LU2468319806.SGD","LU0310800379.SGD","IE00BJT1NW94.SGD","LU1989772923.USD","LU1244550221.USD","LU2133065610.SGD","LU2237443549.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU1267930490.SGD","LU0820561909.HKD","LU2089284900.SGD","LU1934455863.HKD","LU1023059063.AUD","BK4588","LU1718418525.SGD","SG9999015945.SGD","BK4534","LU0256863811.USD","LU1929549753.HKD","LU2129689514.USD","LU0256863902.USD","LU0472753341.HKD","LU0320765646.SGD","LU1430594728.SGD","LU1983299246.USD","IE000F7OJYX1.SGD","LU1934455277.USD","LU1003077747.HKD","LU0965509283.SGD","LU1496350171.SGD","LU0098860793.USD","LU0861579265.USD","LU0029864427.USD","IE00B3PB1722.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134726052","title":"Outlook Therapeutics宣布FDA接受其重新提交的Ons-5010/Lytenava™生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1134726052","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134726052?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:02","pubTimestamp":1781611349,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc. 宣布，美国食品药品监督管理局已正式接受其针对湿性年龄相关性黄斑变性治疗药物Ons-5010/Lytenava™（Bevacizumab-Vikg）重新提交的生物制剂许可申请。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124481970","title":"Calidi Biotherapeutics获美国FDA对Cld-401的积极Pre-IND反馈，就当前开发策略达成一致，推进首次人体研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1124481970","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124481970?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:01","pubTimestamp":1781611291,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics公司宣布，其候选疗法Cld-401已获得美国食品药品监督管理局（FDA）积极的Pre-IND（研究性新药申请前）会议反馈。这一进展标志着监管机构与公司就Cld-401当前的整体开发策略达成共识，为推进该疗法进入首次人体临床研究扫清了关键路径。公司正基于此反馈，积极准备后续的IND申请工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178176076","title":"Calidi Biotherapeutics：目标年底前提交CLD-401监管申请，首个人体试验拟于2027年初启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1178176076","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178176076?lang=zh_cn&edition=full","pubTime":"2026-06-16 20:00","pubTimestamp":1781611259,"startTime":"0","endTime":"0","summary":"Calidi Biotherapeutics公司宣布，其目标是在今年年底前完成候选疗法CLD-401的监管申请提交。若进展顺利，公司计划于2027年初启动该疗法的首次人体临床试验。这一时间表标志着该公司在推进其新型生物治疗平台方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169654490","title":"Moderna任命Ester Banque为首席商务官，2026年6月15日生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1169654490","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169654490?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:33","pubTimestamp":1781609595,"startTime":"0","endTime":"0","summary":"Moderna, Inc. 宣布，已任命Ester Banque为公司首席商务官，此项任命自2026年6月15日起正式生效。作为首席商务官，Banque将全面负责公司的全球商业战略、市场准入及销售运营，领导团队推动公司产品组合的商业化进程。此次高层人事变动旨在加强Moderna在全球商业运营方面的领导力，以应对不断变化的市场环境并把握未来的增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4548","MRNX","BK4533","BK4588","BK4139","BK4501","BK4585","BK4534","MRNA","BK4568","BK4551","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155700158","title":"Moderna总裁斯蒂芬·霍格扩大职责范围，将负责传染病、Intismeran及罕见病业务板块的运营监督","url":"https://stock-news.laohu8.com/highlight/detail?id=1155700158","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155700158?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:33","pubTimestamp":1781609594,"startTime":"0","endTime":"0","summary":"Moderna公司宣布，其总裁斯蒂芬·霍格将承担更广泛的职责，负责监督公司传染病业务、Intismeran以及罕见病业务板块的运营工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4532","BK4533","BK4551","BK4568","BK4588","BK4139","MRNA","BK4534","BK4585","MRNY","MRNX","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130256716","title":"Acumen Pharmaceuticals宣布提名两款增强型脑部递送™ (EbD™) 开发候选药物用于治疗阿尔茨海默病","url":"https://stock-news.laohu8.com/highlight/detail?id=1130256716","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130256716?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:31","pubTimestamp":1781609510,"startTime":"0","endTime":"0","summary":"Acumen Pharmaceuticals, Inc. 宣布，已提名两款基于其增强型脑部递送™ (EbD™) 技术平台的开发候选药物，用于治疗阿尔茨海默病。此举标志着该公司在攻克这一神经退行性疾病领域的研发管线取得了重要进展。\n这两款候选药物的提名，旨在利用其专有的EbD™技术，更有效地将治疗性分子递送至大脑靶点，以期改善阿尔茨海默病患者的治疗效果。公司计划推进相关临床前及后续的临床开发工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","ABOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188200472","title":"Avalo Therapeutics扩充管线，引入长效新一代抗IL-1β抗体AVTX-010","url":"https://stock-news.laohu8.com/highlight/detail?id=1188200472","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188200472?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:06","pubTimestamp":1781607986,"startTime":"0","endTime":"0","summary":"Avalo Therapeutics公司宣布其研发管线迎来新成员——AVTX-010。这是一款长效的新一代抗白细胞介素-1β（IL-1β）抗体，旨在为相关疾病领域提供创新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105680375","title":"帕西莎治疗公司修正方案：治疗期延至18个月，新增核磁共振与认知测量","url":"https://stock-news.laohu8.com/highlight/detail?id=1105680375","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105680375?lang=zh_cn&edition=full","pubTime":"2026-06-16 19:04","pubTimestamp":1781607863,"startTime":"0","endTime":"0","summary":"帕西莎治疗公司（Pasithea Therapeutics Corp.）宣布，对其治疗方案进行了重要修正。根据最新调整，患者治疗周期将延长至18个月，并新增了核磁共振扫描与认知测量两项关键评估内容。这一系列修正旨在更全面地监测治疗效果与患者长期状况，为临床研究提供更为详尽的数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}